Adverum Biotechnologies Inc (NASDAQ:ADVM) reached a new 52-week high during trading on Thursday . The company traded as high as $8.18 and last traded at $8.13, with a volume of 65154 shares. The stock had previously closed at $6.45.
A number of equities research analysts recently commented on the stock. Cowen reaffirmed a “buy” rating on shares of Adverum Biotechnologies in a report on Thursday. ValuEngine cut shares of Adverum Biotechnologies from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. BidaskClub raised shares of Adverum Biotechnologies from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. Finally, Zacks Investment Research cut shares of Adverum Biotechnologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $6.55.
The stock has a market cap of $404.08 million, a P/E ratio of -6.89 and a beta of 3.24. The company has a current ratio of 18.20, a quick ratio of 18.20 and a debt-to-equity ratio of 0.12.
In other Adverum Biotechnologies news, Director James Paul Scopa purchased 20,000 shares of the business’s stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $6.71 per share, for a total transaction of $134,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ADVM. Wells Fargo & Company MN boosted its position in Adverum Biotechnologies by 169.5% during the third quarter. Wells Fargo & Company MN now owns 34,142 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 21,474 shares during the period. Bank of New York Mellon Corp boosted its position in Adverum Biotechnologies by 17.8% during the third quarter. Bank of New York Mellon Corp now owns 219,784 shares of the biotechnology company’s stock valued at $1,330,000 after buying an additional 33,185 shares during the period. BlackRock Inc. boosted its position in Adverum Biotechnologies by 11.6% during the third quarter. BlackRock Inc. now owns 3,690,235 shares of the biotechnology company’s stock valued at $22,326,000 after buying an additional 382,786 shares during the period. Dimensional Fund Advisors LP boosted its position in Adverum Biotechnologies by 2.2% during the third quarter. Dimensional Fund Advisors LP now owns 1,641,732 shares of the biotechnology company’s stock valued at $9,933,000 after buying an additional 35,325 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Adverum Biotechnologies by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 2,767,090 shares of the biotechnology company’s stock valued at $16,740,000 after buying an additional 214,770 shares during the period. Institutional investors and hedge funds own 59.75% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Adverum Biotechnologies (ADVM) Reaches New 1-Year High at $8.18” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2019/05/16/adverum-biotechnologies-advm-reaches-new-1-year-high-at-8-18.html.
About Adverum Biotechnologies (NASDAQ:ADVM)
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema.
Featured Article: What is an SEC Filing?
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.